6 registrations that name exenatide as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 6 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 6 registrations
RecruitingNCT05482789
Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes
Phase 4
Maisa N. Feghali, MD
About 13 people
Started Apr 12, 2023
In plain words A Phase 4 study of exenatide in female participants 18 to 50, run by Maisa N. Feghali, MD. It plans to enroll about 13 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 50. Conditions: Gestational Diabetes.
Pregnant women (singleton)
Gestational diabetes not requiring medical therapy
Between 18 and 50 years of age
Able to give written informed consent
The exclusion criteria are on the listing.
What it tests, as registered
Exenatide
Registered summary
This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT05663515
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Observational
AstraZeneca
About 24,000 people
Started Sep 30, 2024
In plain words An observational study of exenatide in people 18 to 99, run by AstraZeneca. It plans to enroll about 24,000 people at 8 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 99. Conditions: Pancreatic Cancer.
Aged 18 years or older at the index date
Individual level data on prescriptions, diagnoses and medical history is available for a minimum of 12 months prior to the index date
A diagnosis of T2DM on index date or prior to index date
One incident prescription (or incident dispensed prescription) for exenatide (BYETTA or BYDUREON/ BYDUREON BCise) between the start and 12 months before the end of the study period.
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Exenatide; Non-GLP-1 RA based glucose lowering drugs
Registered summary
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. The full summary is on the listing.
Where, as registered
No US site; United Kingdom (2), Denmark (1), Finland (1), France (1), Norway (1), Spain (1), Sweden (1).
RecruitingNCT07309094
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Observational
Cardenal Herrera University
About 250 people
Started Sep 15, 2023
In plain words An observational study of exenatide in people 18 to 90, run by Cardenal Herrera University. It plans to enroll about 250 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; Chronic Kidney Disease Stage 1; Chronic Kidney Disease Stage 2; Obesity; Diabetes Mellitus, Type 2.
> or = 18 years of age
diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis
had uncontrolled T2DM, CVDs and/or obesity
willing to participate in the study and sign informed consent
The exclusion criteria are on the listing.
What it tests, as registered
GLP-1 receptor agonist; SGLT2 inhibitor; Tirzepatide; Other drugs
Registered summary
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
RecruitingNCT05356104
GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Phase 2
Chinese University of Hong Kong
About 110 people
Started May 25, 2022
In plain words A Phase 2 study of exenatide in people 55 to 80, run by Chinese University of Hong Kong. It plans to enroll about 110 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 55 to 80. Conditions: Cerebral Small Vessel Disease.
Chinese ethnicity;
Age 55 to 80 years old;
Age-Related White Matter Change (ARWMC) Scale of 2 or early 3 in FLAIR MRI;
Modified Functional Ambulation Classification 5 or above;
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
GLP-1 receptor agonist
Registered summary
Cerebral small vessel disease (cSVD), a result of neurovascular cell dysfunction, is a major cause of stroke, dementia and mobility problems worldwide. Vascular risk factor control alone may not be sufficient to prevent the development of vascular cognitive impairment (VCI) in patients with cSVD according to previous clinical trials. The presence of glucagon-like peptide-1 receptor (GLP-1R) in cerebral microglia may reveal a potential therapeutic target for prevention of cSVD progression and its disabling clinical outcomes. The full summary is on the listing.
Where, as registered
No US site; China (1), Hong Kong (1).
RecruitingNCT05662189
Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus
No phase
Azienda Ospedaliero-Universitaria di Parma
About 70 people
Started Mar 15, 2022
In plain words A study of exenatide in people 18 to 75, run by Azienda Ospedaliero-Universitaria di Parma. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism.
Age ≥18 years; ≤ 75 years
Both sexes
Good health
Absence of exclusion criteria
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
68Ga-exendin-4; mixed meal test
Registered summary
The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.
Where, as registered
No US site; Italy (1).
RecruitingNCT07347080
A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus
Early phase 1
The First Affiliated Hospital of Henan University of Science and Technology
About 9 people
Started Jan 20, 2026
In plain words An early phase 1 study of exenatide in people 18 to 65, run by The First Affiliated Hospital of Henan University of Science and Technology. It plans to enroll about 9 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: T2DM.
Chinese male or female， 18≤age≤-65 years .
Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2024 Edition)" diagnostic criteria.
Patients who have failed treatment with diet and exercise alone, or metformin monotherapy, or a stable regimen for 12 weeks of metformin (dose ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day) combined with one of the following oral…
18.5 kg/m²≤Body Mass Index (BMI) ≤40.0 kg/m² at screening and enrollment
3 more inclusion criteria and the exclusion criteria are on the listing.
Primary Objectives: •To evaluate the safety and tolerability of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059）in Chinese subjects with T2DM. Secondary Objectives: * To characterize the pharmacokinetic (PK) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（CR059） in Chinese subjects with T2DM; * To characterize the pharmacodynamic (PD) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059） in Chinese subjects with T2DM; * To evaluate the immunogenicity of a single dose of Exenatide Circular RNA-Lipid… The full summary is on the listing.